Dubermatinib Uses, Dosage, Side Effects and more
Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).
Trade Name | Dubermatinib |
Generic | Dubermatinib |
Dubermatinib Other Names | Dubermatinib |
Type | |
Formula | C24H30ClN7O2S |
Weight | Average: 516.06 Monoisotopic: 515.1870221 |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |